Home>Topics>Companies>Orexigen Therapeutics

Orexigen Therapeutics

  1. All
  2. Commentary
  3. Headlines
  1. Possible Delay In Orexigen Approval Process In Europe

    Headlines

    Thu, 31 Jul 2014

    By Spencer Osborne : Orexigen (NASDAQ: OREX ) announced on July 30 that the company ..... the company had previously addressed. Orexigen also stated that CHMP wanted additional ..... new issues were substantial enough that Orexigen is seeking a 30 day extension. Orexigen

  2. Orexigen receives 180 LOI from EMA regarding NB32 submission

    Headlines

    Wed, 30 Jul 2014

    Agency sends a 180 List of Outstanding Issues to Orexigen Therapeutics ( OREX -2.7% ) regarding its Marketing Authorization ..... investigational drug candidate for weight loss. Orexigen believes it addressed the key questions the EMA

  3. The Anti-Obesity Space Is Not As Simple As Some Think

    Headlines

    Fri, 20 Jun 2014

    think of Vivus ( VVUS ), Arena Pharmaceuticals ( ARNA ), and Orexigen ( OREX ). These three companies have been the center of attention ..... two already have products on the market, and the third, Orexigen , is likely to see its anti-obesity drug approved this Fall

  4. What Will It Take For Arena Stock To Rise?

    Headlines

    Mon, 16 Jun 2014

    the equity to appreciate. The frustrations seem to have come to a head following the combination of a delay for competitor Orexigen combined with a 23% uptick in week over week prescription sales numbers last week. Investors seem to feel that these two

  5. UPDATE 2-FDA delays decision on Orexigen's obesity drug by 3 months

    Headlines

    Wed, 11 Jun 2014

    June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug, contrave, by three months, sending the...

  6. FDA delays decision on Orexigen's obesity drug by three months

    Headlines

    Wed, 11 Jun 2014

    June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed its decision on the marketing application of its obesity drug, contrave, by three months, sending its...

  7. Diet drug makers Vivus, Orexigen fall ahead of FDA decision

    Headlines

    Tue, 17 Jul 2012

    (Reuters) - Shares of weight-loss drug makers Vivus Inc and Orexigen Therapeutics Inc fell ahead of an anticipated deadline by the end of Tuesday for the U.S. Food and Drug Administration to decide...

« Prev123Next »
Content Partners